Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to major challenges in the therapeutic management of patients living with multiple sclerosis (PLwMS), particularly regarding the use of disease-modifying therapies. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedotti, Rosetta, Muros-Le Rouzic, Erwan, Raposo, Catarina, Schippling, Sven, Jessop, Nikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349416/
https://www.ncbi.nlm.nih.gov/pubmed/34411984
http://dx.doi.org/10.1016/j.msard.2021.103203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349416/
https://www.ncbi.nlm.nih.gov/pubmed/34411984
http://dx.doi.org/10.1016/j.msard.2021.103203

Ejemplares similares